MID-TERM CLINICAL OUTCOMES OF ZOTAROLIMUS-ELUTING STENT IN PATIENTS WITH STABLE ANGINA PECTORIS

Abstract

Objectives: The study was designed to evaluate the safety and effectiveness ofthe Endeavor zotarolimus-eluting stent (ZES) for the treatment of stable coronaryartery disease.

Methodology: This was a cross sectional descriptive study. Patients who wereadmitted to Cardiology Unit of Lady Reading Hospital, Peshawar, through OPD orcasualty department, fulfilling the inclusion criteria were enrolled in the study.This study included all the patients with stable coronary artery disease who hadreceived Endeavor stents from January 2010, to March 2011. Total studyduration was 15 months. The primary end point was the rate of major adversecardiac events (MACE) at 12 months. All patients who underwent PCI withEndeavor stent implant for stable angina pectoris were followed up andreassessed after 12 months from the index procedure.

Results: A total of 128 patients were included in the study. Mean age was 54±2.4years. Male were 91 (71.1 %) while females were 37 (28.9). Of these 49.2%were hypertensive, 28.9% diabetic, 19.5% smokers, and 39.8% dyslipidemics.Overall 12-month outcome rates were: MACE 5.5%; cardiac death 0.8%; STEMI0.8%; NSTEMI 1.6% and revascularization 2.3%.

Conclusion: This study provides important information regarding the mid-termsafety and efficacy of the Endeavor zotarolimus-eluting stent. Frequency ofclinical outcomes including cardiac death, myocardial infarction, andrevascularization were low and consistent with pooled results of other majortrials.